0.280
0.13 (85.43%)
| Previous Close | 0.151 |
| Open | 0.151 |
| Volume | 23,778 |
| Avg. Volume (3M) | 3,218 |
| Market Cap | 583,100,736 |
| Price / Earnings (Forward) | 6.73 |
| Price / Sales | 4.63 |
| Price / Book | 4.31 |
| 52 Weeks Range | |
| Earnings Date | 28 Aug 2025 |
| Operating Margin (TTM) | -57,123.49% |
| Diluted EPS (TTM) | -2.25 |
| Quarterly Revenue Growth (YOY) | -26.20% |
| Current Ratio (MRQ) | 1.57 |
| Operating Cash Flow (TTM) | -157.81 M |
| Levered Free Cash Flow (TTM) | -79.30 M |
| Return on Assets (TTM) | -73.34% |
| Return on Equity (TTM) | -3,383.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Opthea Limited | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.50 |
|
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Institutions | 5.06% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |